Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783391 | 1.00 | POLB (0.39) | POLBALOX5ALDH1A1MEN1KMT2A | |
| SCHEMBL9358907 | 0.74 | POLB (0.38) | POLBALDH1A1MEN1KMT2ACTSL | |
| SCHEMBL27613087 | 0.73 | — | — | |
| SCHEMBL8829761 | 0.72 | CTSL (0.41) | POLBALDH1A1MEN1KMT2ACTSL | |
| SCHEMBL6095759 | 0.70 | POLB (0.42) | POLBALOX5ALDH1A1MEN1KMT2A | |
| SCHEMBL1568140 | 0.70 | POLB (0.42) | POLBALOX5ALDH1A1MEN1KMT2A | |
| SCHEMBL12398491 | 0.69 | CTSK (0.34) | POLBALOX5CTSLCTSBCTSS | |
| SCHEMBL4055842 | 0.69 | POLB (0.35) | POLBALDH1A1MEN1KMT2A | |
| SCHEMBL14142750 | 0.69 | POLB (0.35) | POLBALDH1A1MEN1KMT2A | |
| SCHEMBL4183134 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| US-6916942-B2 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040225009-A1 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| EP-1251846-B1 | C-4 CARBONATE TAXANES | BRISTOL MYERS SQUIBB CO (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6750246-B1 | NOVEL ORALLY ACTIVE PACLITAXEL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | CA4, CA14, CA13 | POLB 724/4885ALOX5 2476/4885ALDH1A1 2676/4885 |
| US-20040225009-A1 | Process for the preparation of C-4 carbonate taxanes | CA4, CA14, CDK4 | POLB 807/4885ALOX5 3608/4885ALDH1A1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.